Literature DB >> 3869433

In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents.

D Henry, A G Skidmore, J Ngui-Yen, A Smith, J A Smith.   

Abstract

A total of 745 gram-negative and 313 gram-positive clinical isolates were tested against enoxacin, ticarcillin plus clavulanic acid, aztreonam, imipenem, and piperacillin and compared with commonly used antimicrobial agents. Ticarcillin plus clavulanic acid, imipenem, and piperacillin were active against Pseudomonas aeruginosa and Acinetobacter spp. and most Pseudomonas spp. Aztreonam was active against members of the family Enterobacteriaceae but was less effective against the nonfermenters. Enoxacin was active against the Enterobacteriaceae, P. aeruginosa, the staphylococci, and most Acinetobacter spp. but was less active against Pseudomonas spp. and streptococci. Imipenem was very active against all gram-positive and -negative organisms tested except for Pseudomonas maltophilia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3869433      PMCID: PMC180229          DOI: 10.1128/AAC.28.2.259

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside.

Authors:  G W White; J B Malow; V M Zimelis; H Pahlavanzadeh; A P Panwalker; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

2.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

3.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

4.  Occurrence and expression of imipemide (N-formimidoyl thienamycin) resistance in clinical isolates of coagulase-negative staphylococci.

Authors:  R M Blumenthal; R Raeder; C D Takemoto; E H Freimer
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

5.  Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.

Authors:  R B Sykes; D P Bonner; K Bush; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

6.  In vitro studies of piperacilin, a new semisynthetic penicillin.

Authors:  D J Winston; D Wang; L S Young; W J Martin; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

7.  In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.

Authors:  S A Chartrand; R K Scribner; A H Weber; D F Welch; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

8.  Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens.

Authors:  J R Carlson; S A Thornton; H L DuPont; A H West; J J Mathewson
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

9.  In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.

Authors:  V W Horadam; J D Smilack; C L Montgomery; J Werringloer
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

10.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

View more
  8 in total

1.  Discrepancies between disk diffusion and broth susceptibility studies of the activity of ticarcillin plus clavulanic acid against ticarcillin-resistant Pseudomonas aeruginosa.

Authors:  F A Manian; R H Alford
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

2.  Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid.

Authors:  P C Fuchs; R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

Review 3.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

4.  [Susceptibility of clinically important Bacteroides species against enoxacin-metronidazole and enoxacin-clindamycin combinations].

Authors:  W R Heizmann; H Werner; R Schmid
Journal:  Infection       Date:  1989       Impact factor: 3.553

Review 5.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

6.  Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Authors:  G H Talbot; P A Cassileth; L Paradiso; R Correa-Coronas; L Bond
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  In vitro susceptibility of Citrobacter species to various antimicrobial agents.

Authors:  G Samonis; D H Ho; G F Gooch; K V Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 8.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.